In the BioHarmony Drug Report Database
Inotuzumab ozogamicin
Besponsa (inotuzumab ozogamicin) is an antibody pharmaceutical. Inotuzumab ozogamicin was first approved as Besponsa on 2017-06-28. It is used to treat precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat precursor cell lymphoblastic leukemia-lymphoma. The pharmaceutical is active against B-cell receptor CD22.
Trade Name
|
Besponsa |
|---|---|
Common Name
|
inotuzumab ozogamicin |
ChEMBL ID
|
CHEMBL2108611 |
Indication
|
precursor cell lymphoblastic leukemia-lymphoma |
Drug Class
|
Monoclonal antibodies: humanized, tumors as target; antibiotics (Micromonospora strains) |
Image (chem structure or protein)
